The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1451
ISSUE1451
September 15, 2014
Vorapaxar (Zontivity) for Prevention of Thrombotic Cardiovascular Events
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Vorapaxar (Zontivity) for Prevention of Thrombotic Cardiovascular Events
September 15, 2014 (Issue: 1451)
The FDA has approved vorapaxar (Zontivity – Merck), an
oral protease-activated receptor-1 (PAR-1) antagonist,
for use with aspirin and/or clopidogrel to reduce the risk
of thrombotic cardiovascular events in patients with
peripheral arterial...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.